TTR and amyloidosis: Other alternative methods to deliver this system could be, as mentioned above, the use of AAVs as used in a clinical trial for CEP290 (NCT03872479),86 or Cas9 delivered as mRNA in a nanoparticle, as previously shown for liver delivery in patients with transthyretin amyloidosis.87